TG Therapeutics Company Profile (NASDAQ:TGTX)

Analyst Ratings

Consensus Ratings for TG Therapeutics (NASDAQ:TGTX) (?)
Ratings Breakdown: 5 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 3.17)
Consensus Price Target: $25.00 (323.01% upside)

Analysts' Ratings History for TG Therapeutics (NASDAQ:TGTX)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Roth CapitalReiterated RatingBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/27/2016SunTrust Banks Inc.Initiated CoverageBuy -> Buy$7.22 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2016HC WainwrightReiterated RatingBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Raymond James Financial Inc.Initiated CoverageStrong-Buy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2015MLV & Co.Set Price TargetBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for TG Therapeutics (NASDAQ:TGTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.36)($0.28)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2016Q4($0.32)($0.37)$38.10 million$38.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.34)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.32)($0.38)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115($0.33)($0.39)$38.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015Q414($0.26)($0.48)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q214($0.32)($0.51)$38.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/22/2014($0.28)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.19)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014Q413($0.18)($0.19)$40.00 million$38.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2013Q313($0.22)($0.62)$0.03 million$0.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q213($0.16)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TG Therapeutics (NASDAQ:TGTX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.37)($0.37)($0.37)
Q2 20162($0.29)($0.26)($0.28)
Q3 20162($0.31)($0.27)($0.29)
Q4 20162($0.34)($0.29)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TG Therapeutics (NASDAQ:TGTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for TG Therapeutics (NASDAQ:TGTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/18/2016Sean A PowerCFOSell10,000$10.12$101,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2016Sean A PowerCFOSell22,790$11.21$255,475.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2015William James KennedyDirectorSell17,000$17.08$290,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Sean A PowerCFOSell50,054$16.46$823,888.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015Sean A PowerCFOSell23,800$15.50$368,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015Sean A PowerCFOSell66,401$16.40$1,088,976.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Sean A PowerCFOSell54,057$16.40$886,534.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014Michael S WeissMajor ShareholderSell210,618$16.44$3,462,559.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014Sean A PowerCFOSell38,041$16.44$625,394.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2013Michael Weissmajor shareholderBuy10,000$3.43$34,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for TG Therapeutics (NASDAQ:TGTX)
DateHeadline
07/28/16 07:04 PM"TG Therapeutics, Inc. (TGTX) - Financial and Strategic SWOT Analysis Review" now available at Fast Market Research
07/27/16 07:12 PMTG Therapeutics Inc. (TGTX) Jumps 9.23% on July 27 - Equities.com
07/26/16 10:17 AMTG Therapeutics, Inc. (TGTX) Updated Price Targets - FTSE News
07/22/16 06:37 PMTG Therapeutics, Inc. (NASDAQ:TGTX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/22/16 06:37 PMTG Therapeutics Incorporated (NASDAQ:TGTX) Shorted Shares Increased By 6.81% - Consumer Eagle
07/21/16 09:36 AMEquity Roundup: Stock Performance Focus on TG Therapeutics, Inc. (NASDAQ:TGTX) - Press Telegraph
07/20/16 07:49 PMInvestor Watch: Volatility Recap on Shares of: TG Therapeutics, Inc. (NASDAQ:TGTX) - Engelwood Daily
07/20/16 07:49 PMDoes TG Therapeutics Inc Have Any Gas After Today's Huge Increase? - Consumer Eagle
07/20/16 07:49 PMNew Broker Ratings For TG Therapeutics, Inc. (TGTX) - FTSE News
07/20/16 07:49 PMTG Therapeutics Inc. (TGTX) Hits New 52-week Low During July 18 Session - Equities.com
07/20/16 07:49 PMTG Therapeutics Inc. (TGTX) Jumps 5.33% on July 20 - Equities.com
07/18/16 09:06 AMHow Analysts Feel About TG Therapeutics Inc (NASDAQ:TGTX)? - Press Telegraph
07/16/16 06:05 PMShares Experiencing a Downtrend: TG Therapeutics, Inc. (NASDAQ:TGTX) - TGP
07/16/16 06:05 PMTG Therapeutics, Inc. (NASDAQ:TGTX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 12:05 PMTG Therapeutics Inc Realized Volatility Hits Extreme Level - CML News
07/14/16 10:24 AMTrading Performance and Target Watch for TG Therapeutics, Inc. (NASDAQ:TGTX) - Press Telegraph
07/12/16 07:01 PMOption Market: TG Therapeutics Inc Risk Hits An Extreme High - CML News
07/12/16 07:01 PMTG Therapeutics Incorporated (NASDAQ:TGTX) Short Interest Decreased By 4.05% - Press Telegraph
07/11/16 08:52 AMTG Therapeutics Inc Q1 2016 Institutional Investor Sentiment Better Than Expected - Press Telegraph
07/11/16 08:52 AMStock Rating Watch and Earnings Insight for TG Therapeutics, Inc. (NASDAQ:TGTX) - Press Telegraph
07/09/16 06:01 PMAre Analysts Bearish TG Therapeutics Inc (NASDAQ:TGTX) After Last Week? - Press Telegraph
07/08/16 06:42 PMCompany Stock Focus for TG Therapeutics, Inc. (NASDAQ:TGTX): Which Way Will Shares Head? - Press Telegraph
07/08/16 06:42 PMTG Therapeutics, Inc. Stock Momentum Hits Extreme Weakness - CML News
07/08/16 06:42 PMWill TG Therapeutics, Inc. (NASDAQ:TGTX) Surprise Analysts? - Investor Newswire
07/08/16 06:42 PMBroker Outlook For TG Therapeutics, Inc. (TGTX) - Fiscal Standard
07/06/16 07:13 PMTG Therapeutics Inc. (TGTX) Jumps 5.12% on July 04 - Equities.com
07/02/16 06:14 PMTG Therapeutics Inc. (TGTX) Hits New 52-week Low During June 30 Session - Equities.com
07/01/16 06:49 PMTG Therapeutics Inc Stock Is Rising Now - Engelwood Daily
07/01/16 06:49 PMCovering the Bases on TG Therapeutics, Inc. (NASDAQ:TGTX): Where is the Stock Going? - Press Telegraph
07/01/16 06:49 PMTG Therapeutics, Inc. (NASDAQ:TGTX) Earnings Glance and Target Price Review - Engelwood Daily
06/29/16 09:32 AMIt Seems TG Therapeutics Inc Will Go Down. Have Another Big Decline - Engelwood Daily
06/28/16 06:41 PMWhat Will Happen to TG Therapeutics Inc Next? The Stock Just Declined A Lot - Press Telegraph
06/28/16 06:41 PMTG Therapeutics Incorporated (NASDAQ:TGTX) Short Interest Decreased By 4.05% - Engelwood Daily
06/28/16 06:41 PMTG Therapeutics, Inc. (NASDAQ:TGTX) Company Rating and Target Watch - Telanagana Press
06/27/16 06:39 PMShare Update and Earnings Review for TG Therapeutics, Inc. (NASDAQ:TGTX) - Press Telegraph
06/27/16 08:43 AMTG Therapeutics, Inc. (TGTX) Broker Price Targets For The Coming Week - Fiscal Standard
06/26/16 05:42 PMHow Analysts Rated TG Therapeutics Inc (NASDAQ:TGTX) Last Week? - Engelwood Daily
06/26/16 05:42 PMCan TG Therapeutics, Inc. (NASDAQ:TGTX) Keep Up with Analyst Expectations? - Investor Newswire
06/23/16 09:21 AMStock Buzz: TG Therapeutics, Inc. (NASDAQ:TGTX) - iStreetWire
06/23/16 09:21 AMTG Therapeutics Inc. (TGTX) Hits New 52-week Low During June 21 Session - Equities.com
06/16/16 11:16 AMTG Therapeutics Inc. (TGTX) Hits New 52-week Low During June 14 Session - Equities.com
06/14/16 04:20 PMTG THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/12/16 09:23 AMCombination of TGR-1202 + Ibrutinib appears well-tolerated and active in relapsed/refractory CLL patients treated with the combination
06/12/16 09:23 AMTG Therapeutics (TGTX) Announces Presentation of TGR-1202 Data in CLL, NHL
06/10/16 09:51 AMTG Therapeutics (TGTX) Announces Presentation of TGR-1202 Data in CLL, NHL - StreetInsider.com
06/10/16 08:39 AMTG Therapeutics, Inc. Announces Data from TGR-1202 in Combination with Ibrutinib as well as Recaps Long-Term Safety and Efficacy Data of TGR-1202 in CLL and NHL at the 21st European Hematology Association Annual Congress - [at noodls] - June 10, 2016 NEW YORK, June 10, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced data presented during the 21 Annual Congress of the European Hematology Association (EHA) being ...
06/08/16 07:19 PMTG THERAPEUTICS INC. (NASDAQ:TGTX) Financial Condition Compared to S&P 500 - CML News
06/08/16 09:54 AMCompany Update (NASDAQ:TGTX): TG Therapeutics Inc Announces First Patient Enrolled in the Registration-Directed ... - Smarter Analyst
06/07/16 07:03 PMWeak On High Volume: TG Therapeutics (TGTX) - TheStreet.com
06/07/16 09:40 AMSunTrust Robinson Humphrey Initiates Coverage on TG Therapeutics Inc to Buy - Trade Calls

Social

About TG Therapeutics

TG Therapeutics logoTG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TGTX
  • CUSIP:
Key Metrics:
  • Previous Close: $5.91
  • 50 Day Moving Average: $6.29
  • 200 Day Moving Average: $8.02
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $319.60M
  • Beta: 2.53
  • Current Year EPS Consensus Estimate: $-1.15 EPS
  • Next Year EPS Consensus Estimate: $-1.21 EPS
Additional Links:
TG Therapeutics (NASDAQ:TGTX) Chart for Saturday, July, 30, 2016